A Phase II Trial of Bortezomib and Vorinostat in Mantle Cell Lymphoma and Diffuse Large B-cell Lymphoma

ConclusionThe combination of bortezomib and vorinostat is safe and has modest activity in MCL and limited activity in DLBCL.
Source: Clinical Lymphoma Myeloma and Leukemia - Category: Cancer & Oncology Source Type: research